priors.science/reviews/adhd-pharmacotherapy

Adhd Pharmacotherapy

The current evidence on 5 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

6claims tracked
5assessed
48primary papers reviewed
4 Oct 2026latest evidence review
1 Established · 2 Likely · 1 Uncertain · 1 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Viloxazine and guanfacine as approved non-stimulant alternatives for ADHDNon StimulantEstablished90%10
Stimulants cause minor cardiovascular changes with rare serious eventsSafety MonitoringLikely81%10
Long-term stimulant use does not reliably prevent functional impairments in ADHDLong Term OutcomesLikely74%10
Atomoxetine effective non-stimulant option for attention-deficit/hyperactivity disorderNon StimulantLong-standingUncertain66%9
Stimulants most effective pharmacotherapy for attention-deficit/hyperactivity disorderStimulant EfficacyDoubtful40%9
Track Adhd Pharmacotherapy.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.